The clinical studies were performed to identify the potential benefits of Youngevity’s signature core products, Beyond Tangy Tangerine® and Ultimate Classic®. Youngevity’s mission was to truly understand and clinically substantiate the health promoting benefits of these two products. Individually, each product targets specific areas, needs, and nutritional deficiencies of the body.
Multiple studies were recommended by Clemson University scientists to provide a comprehensive evaluation of the Youngevity® products. Specific biomarkers were chosen to study in the areas of safety, inflammation, and when Beyond Tangy Tangerine® and Ultimate Classic® were administered to cancer cell cultures.
Youngevity® Clinical Research Study Highlights:
When Beyond Tangy Tangerine® and Ultimate Classic® were administered to healthy human cell lines, they did not induce or create any inflammatory response in levels above and below the recommended dosage. Beyond Tangy Tangerine® and Ultimate Classic® showed inflammation protective properties and heightened the body’s protective responses to possible inflammation.
When Beyond Tangy Tangerine® and Ultimate Classic® were administered to healthy human colon cells, there was no significant death of healthy human cells compared to cancerous colon cells. Ultimate Classic® killed 95% of cancerous colon cells, 65% of cancerous liver cells, 65% of cancerous stomach cells, and 30% of cancerous breast cells. Beyond Tangy Tangerine® killed 60% of cancerous colon cells, 65% of cancerous liver and stomach cells, and 30% of cancerous breast cells.
Beyond Tangy Tangerine® and Ultimate Classic® both exhibited efficient inhibition on proliferation of cancerous cells at the recommended dosage levels. Both products showed there was inhibition of the growth of more cancerous cells, preventing further malignant multiplication and growth of unhealthy cells.
This was also featured on Reuters.
Read more here: [link to www.heraldonline.com